13 Jan 05
Morgan Levy (formally E-Focus Resourcing) has pleasure in announcing that we have re-branded to Morgan Levy with effect from January 2005.
GARY M BRITNELL
20 Dec 04
The outlook for hepatocellular carcinoma (HCC) sufferers is bleak - current medication has a five-year survival rate for those with liver cancer of less than 5% in the developed world and even lower in developing countries. However, patients in trials of a new drug called Sorafenib have seen their survival times double. Datamonitor's Dr Lorna Fern investigates...
14 Dec 04
Britain’s hospital patients, led by Claire Rayner, today called for healthcare professionals to get behind the UK’s first ever Clean Hospitals Summit, planned for April 14-15, 2005.
Anna Harris/ Alan Murray
10 Dec 04
The recent announcement by the FDA's associate director for science and medicine that sales of GlaxoSmithKline's asthma drug Serevent should be restricted, or halted, led to an estimated 3.8% fall in the company's share price. However, Datamonitor's Laura Harris comments that, with Seretide accounting for the majority of GSK's asthma sales, the panic may be premature.
08 Dec 04
At a recent hearing into the Vioxx affair, the FDA's Dr David Graham named five drugs that he considers too dangerous to be on the market. However, in his testimony, Dr Graham also cited Sanofi-Aventis' Arava as a drug he has recommended be withdrawn. Unlike the other five drugs, Arava has largely escaped the media spotlight, but there may yet be some tough questions asked about its safety.
29 Nov 04
Unique intelligence from eyeforpharma: 'Barriers, best practices and measuring ROI for patient compliance programmes'
19 Nov 04
Influenza is a global disease which imposes a huge medical and economic burden inevery country of the world. The UK is no exception with one caveat - the virus is probably monitored and tracked more in the UK than any other country around the globe. Over the years, GPs have played a leading role in estimating the quantitative impact of influenza. This started with the pioneering work of William Pickles in the Wensleydale villages and continued with Edgar Hope-Simpson in Cirencester.
17 Nov 04
School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.
09 Nov 04
Over the past 30 years, numerous clinical trials evaluating a variety of different classes of drugs have conclusively shown the benefit of blood pressure reduction in reducing the risk of strokes and cardiovascular mortality. Moreover, such trials have clearly demonstrated that blood pressure is unlikely to be controlled with a single drug and often two or more therapies are required to achieve blood pressure targets.
05 Nov 04
Altana has announced the delay of its US application for Daxas until late 2005 due to clinical trial enrolment taking longer than originally anticipated. The news will be of further concern to the company's investors, coming on the back of the recent announcement that another of its respiratory drugs, Alvesco, failed to win full FDA approval.
22 Oct 04
Treatment with combined estrogen/progestin doubles the risk of VTE in post-menopausal women and for obese women the risk is even higher, a recent study showed. However millions of women no longer taking HRT remain at risk of osteoporosis, which presents a huge market opportunity for non-hormonal classes in treating and preventing osteoporosis.
15 Oct 04
Recruitment is a very inexact science – the statistics in favour of making the right decision based on the traditional interview alone are horrifyingly low (the percentage is in single figures). This is a fact that has really only been acknowledged in recent years and, as a result, organisations have looked for ways to improve the success rate of their selection choices.
14 Oct 04
The recent government suspension of the manufacturing license for major flu vaccine maker Chiron in the UK has left many countries facing a severe shortage in flu vaccine supply for the 2004-05 season. In the light of previous vaccine provision difficulties, Datamonitor's Laura Harris argues that, in the longer term, cell culture vaccines could resolve the annual flu vaccine quandary...
11 Oct 04
Last week, Merck & Co sent shockwaves through the pharmaceutical market with the announcement that it had voluntarily withdrawn its blockbuster arthritis drug Vioxx. Datamonitor's Adele Schulz examines the likely impact of this event, for the remainder of 2004 and beyond, on both Merck and its rivals...
03 Sep 04
Isotechnika's Q2 loss shows a sharp reversal in fortunes. Profit in 2003 was largely attributable to a research payment for ISA247 from Roche, which has since pulled out of part of the deal. Isotechnika will be hoping that Roche continues to support ISA247 in the field of transplantation, but, says Datamonitor's Timothy Pang, it would be boosted by the cash that a new partner would bring...
01 Sep 04
Due to more and better screening practices leading to earlier diagnosis, survival rates for breast cancer have risen to as high as 87% in some developed countries. But globally, 380,000 people (mainly women) will still die from breast cancer in 2004. Datamonitor's Fleur Pijpers explains that in the future, new targeted therapies could lead to successful treatment for each individual patient...
23 Aug 04
Eventually, methods developed by research laboratories need to be transferable to face the rigours of external validation or the production line. Many researchers, however, are unaware that this procedure must be adequately documented, a crucial issue when it comes to regulation and outsourcing.
Rachel Holdsworth/Geoff Pulham
23 Aug 04
Pharmaceutical practices from manufacturing to marketing are coming under increasing scrutiny from watchdogs, regulators and shareholders. As huge fines and record settlements erode profits, Datamonitor's Andrew Jones argues that pharma companies must focus on tightening compliance...
23 Aug 04
Having worked as a recruitment consultant for six years I soon realised that online recruitment was my main source of applicants. This maybe due to how easy it is for applicants to apply online and more people having Internet access.
Which type of site do you tend to look at on the web? A news site? A site about your hobby or team? A job board such as Pharmiweb?
With more people searching for jobs online, more companies see the benefit and use job boards to direct them to their careers page
Ed Fowler - ebods.com Ltd
18 Aug 04
After my many years of conducting interviews and recruiting for both junior and senior employees, I have come to the conclusion that if there is one single thing that a person can do to secure a second interview or a desired position it is believe in themselves.
12 Aug 04
The trade in discounted prescription drugs between Canada and the US has elicited considerable controversy on both sides of the border. Yet recent figures show that sales of drugs via Canadian pharmacies have not been as great as some had predicted. However, as Datamonitor's David Deon explains, pharmaceutical companies could go further by driving the expansion of online prescribing in the US...
03 Aug 04
Bacterial skin diseases like gangrene can now expect an onslaught of new specialist medications. However, skin infections make up a relatively small proportion of the $20.4 billion annual global antibacterial market, which, says Datamonitor's Amber Gibson, raises questions about why such conditions are the current focus of so much antibacterial product development...
14 Jul 04
What exactly is a Curriculum Vitae? Is it a List of your Skills and Experience? Is it a Mini Biography? Is it a chance to get someone to fully appreciate your Skills and Achievements?
Truth be known, It’s none of these.
23 Jun 04
‘To change Career, or to change Company?’ Although these seven words are easy to utter (and utter you will, over and over again), they are actually very deceptive as really what you are asking is, ‘Which direction should my life now take?’
17 Jun 04
As we all know, interviews come in three forms: The good, the bad, and sometimes… The downright ugly! This is an article about the latter; ugly interviews, from ‘unconventional’ interviewers, who wouldn’t know the words ‘Professional, Un-biased and Independent’ even if they came up and bit them!
11 Jun 04
With several blockbuster biological products approaching patent expiry and the emergence of new approval pathways, the biogenerics segment represents an attractive opportunity for companies looking to escape intensifying competition in the commodity generics sector. However, with the biotech industry preparing significant opposition to any new regulatory initiatives, barriers to market entry could remain high.